Communiqués Larimar Therapeutics, Inc.

Actions

LRMR

US5171251003

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 15:46:02 02/10/2026			Varia. 5j.	Varia. 1 janv.
3,000 ^USD	-1,96%		-7,83%	-19,69%

29/09	Larimar Therapeutics nomme John Harlow au poste de directeur de l’exploitation	MT
29/09	Larimar Therapeutics, Inc. annonce la nomination de John Harlow au poste de président et de directeur de l’exploitation, à compter du 29 septembre 2026	CI

Communiqués

29/09	Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer	AQ
04/08	Larimar: Q2 Earnings Snapshot	AQ
04/08	Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update	AQ
29/06	Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia	AQ
26/06	Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia	AQ
14/05	Larimar: Q1 Earnings Snapshot	AQ
14/05	Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update	AQ
30/04	Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia	AQ
19/03	Larimar: Q4 Earnings Snapshot	AQ
19/03	Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results	AQ
04/03	Larimar Therapeutics to Participate in Upcoming Investor Conferences in March	AQ
25/02	Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering	AQ
24/02	Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026	AQ
18/12	Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
05/11	Larimar: Q3 Earnings Snapshot	AQ
05/11	Larimar Therapeutics Reports Third Quarter 2025 Financial Results	AQ
29/09/25	Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia	AQ
28/09/25	Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia	AQ
14/08/25	Larimar: Q2 Earnings Snapshot	AQ
14/08/25	Larimar Therapeutics Reports Second Quarter 2025 Financial Results	AQ
31/07/25	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares	AQ
30/07/25	Larimar Therapeutics Announces Pricing of Underwritten Public Offering	AQ
29/07/25	Larimar Therapeutics Announces Proposed Underwritten Public Offering	AQ
08/07/25	Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia	AQ
23/06/25	Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program	AQ